These authors concluded that a substantial number of cells in KRAS-mutated benign-looking tumors undergo oncogene-induced senescence, but that KRAS-mutated invasive adenocarcinomas do not undergo senescence due to the inactivation of oncogene-induced senescence effectors such as TP53 and CDKN2A [84]. Here, CDKN2A is linked to adenocarcinoma.